Laboratory of Physical Chemistry for Drug Design

Laboratory of Physical Chemistry for Drug Design

Japanese
professor:Nobutada Tanaka

Research Content

Concept of Structure-Based Drug Design

Research Flow in Our Lab

Protein X-ray Crystallography Workflow

Structure-based virtual screening for chymase inhibitors by in silico fragment mapping

The term chymase refers to a family of chymotrypsin-like serine proteases stored within the secretory granules of mast cells. Recently, a variety of small molecule inhibitors for chymase have been developed with a primary focus on the treatment of cardiovascular diseases. Despite the expected therapeutic benefit of these chymase inhibitors, they have not been used clinically. Here, we attempted to identify new chymase inhibitors using a multistep structure-based virtual screening protocol combined with our knowledge-based in silico fragment mapping technique.
The mapping procedure identified fragments with novel modes of interaction at the oxyanion hole of chymase. Next, we constructed a three-dimensional (3D) pharmacophore model and retrieved eight candidate chymase inhibitors from a commercial database that included approximately five million compounds. This selection was achieved using a multistep virtual screening protocol, which combined a 3D pharmacophore-based search, docking calculations, and analyses of binding free energy. One of the eight compounds exhibited concentration-dependent chymase inhibitory activity, which could be further optimized to develop more potent chymase inhibitors.

3D-Pharmacophore Identification for k-Opioid Agonists Using Molecular Superpositions

In silico study on the interaction of high affinity ligand calystegineB2 with β-glucocerebrosidase

Development and application of new 3D-QSAR analysis using quantum chemistry and multivariate statistics

Hydration site analysis of target proteins and its application for virtual screening of novel lead compound candidates